Solid tumor cell therapy
Non-engineered cell therapy designed to seed immune hubs inside tumors.
Defiant Therapeutics is developing ReCharge, a platform intended to create tertiary lymphoid structures inside solid tumors so the patient’s own immune system can generate local and systemic anti-tumor activity.
What we are building
Single-injection therapy
An intratumoral approach designed to form a miniature lymph-node-like structure directly at the cancer site.
Faster manufacturing
A non-engineered autologous cell therapy workflow targeting treatment readiness in days, not weeks.
Platform potential
A plug-and-play strategy being developed across solid tumor indications where durable immune activation is needed.
Team
Sam Inverso, PhD
Co-founder & CEO
Sam is a scientist and entrepreneur focused on translating platform technologies into venture-backed companies. He co-founded ReadCoor, acquired by 10x Genomics, and brings experience in strategy, partnerships, and company building to Defiant.
Girija Goyal, PhD
Co-founder & CSO
Girija is an immunologist and inventor of the ReCharge platform. Her work at the Wyss Institute spans human immune models, organs-on-chips, diagnostics, and bioinspired therapeutic platforms for challenging diseases.